Abstract:Objective To compare the therapeutic effect of TACE combined with or without endovascular implantation of iodine-125 seeds strand for hepatocellular carcinoma ( HCC) with extensive portal vein tumor thrombus(PVTT)with randomized design.Methods From May-2011 to Dec 2012,62 patients of HCC with extensive PVTT who received TACE were randomized divided into group A ( conbined with , 30 cases)and group B(without,32 cases)endovascular implantation of iodine-125 seeds strand were analyzed retrospectively .TACE was performed after the iodine-125 seed strand implanted in the target segment of PVTT.Adverse events , laboratory tests and abdominal constrast CT results between two groups were compared.Kaplan-Meier method was used for analyzing for survival rate .Results The objective remission rate of lesions was 10.0%(CR in 1 and PR in 6)in group A and 28.1%(CR in 2,PR in 7)in group B(χ2 =3.259,P=0.071).The mean number of iodine-125 seed was 20.4 ±4.4(14-32) for every patient.The recanalization rate of portal vein was 28.1%in group B higher than 0 in group A(χ2 =7.734,P=0.005). Technical success rate was 100.0% for implantation of iodine-125 seeds strand in the target segment of PVTT.No serious procedure related complications occurred in two group .The mean and median survival time was(153.8 ±9.9) d(95%CI:134.5-173.1) and(150.0 ±10.9) d(95%CI:128.6-171.4) in Group A and(221.5 ±19.2)d 95%CI:183.8-259.1)and(190.0 ±24.7)d 95%CI:141.6-238.4)in Group B, respectively(χ2 =10.973,P=0.001)(HR(A︰B) =2.577,95%CI:1.437-4.623,P=0.001).The 90, 180,360 d cumulative survival rates were 89.7%,28.7%and 0 in group A and 96.8%,56.0%and 15.2%in group B,respectively.In group with recanalization of portal vein (group B1,9 cases),the mean and median survival time were(306.9 ±45.6)d(95%CI:217.5-396.2)and(264.0 ±41.7)d(95%CI:182.3-345.7), respectively and the 90,180,360 d cumulative survival rates were 100.0%,87.5%and 40.0%,respectively. While in group without recanalization of portal vein (group B2,23 cases),the mean and median survival time were(189.5 ±16.5) d (95%CI:157.2-221.9) and (175.0 ±20.4) d (95%CI:134.9-215.1), respectively and the 90,180,360 d cumulative survival rates were 95.5%,43.2%and 6.4%,respectively. There was statistically significant difference between two groups (χ2 =5.105,P=0.024)(HR(B2︰B1) =2.960,95%CI:1.100-7.969,P=0.032).Conclusion TACE combined with endovascular implantation of iodine-125 seeds strand is an effective treatment for HCC with extensive PVTT .

Endovascular brachytherapy vs.sequential three-dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus: a comparative study

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

HCC with Main Portal Vein Tumor Thrombus Treated by Stent Placement and TACE Combined with Endovascular Brachytherapy or Three Dimensional Conformal Radiotherapy

Endovascular Brachytherapy Combined with Portal Vein Stenting and Transarterial Chemoembolization Improves Overall Survival of Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus.

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

Combined Three Intervened Treatment of TACE,PEI And PVC in Advanced Liver Cancer

Hepatocellular carcinoma complicated by main portal vein tumor thrombus: treated by portal vein stenting,tansarterial chemoembolization and 3-dimensional conformal radiotherapy

Preliminary Results of Main Portal Vein Tumor Thrombus Treated by Endovascular Brachytherapy Combined with Sorafenib

[Clinical Effect of Terminal Branches Portal Vein Embolization Combined with Transcatheter Arterial Chemoembolization on Liver Neoplasms].

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Portal Vein Stenting Combined 125I Particle Implanted Followed by Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT

Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand

[Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein].

Randomized Comparative Study of HCC with MPVTT Treated by Portal Vein Stent and TACE Combined with or Without Endovascular Implantation of Iodine-125 (125I) Seeds Strand

Irradiation stent with <SUP>125</SUP>I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial

A comparison of treatment combinations with and without radiotherapy for the hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus

A Comparison of Treatment Combinations with and Without Radiotherapy for Hepatocellular Carcinoma with Portal Vein And/or Inferior Vena Cava Tumor Thrombus.